GlaxoSmithKline has rejected a £50bn bid from Unilever to acquire its consumer health joint venture with Pfizer, saying it “fundamentally undervalued” the business and its future prospects.
GSK said it had turned down three approaches, including a £50bn offer comprising £41.7bn in cash and £8.3bn in Unilever shares, received on December 20.
“In this case, after careful review of Unilever’s proposals, we decided that they fundamentally failed to recognise the value and the potential we see for Consumer Healthcare,” said Emma Walmsley, GSK’s chief executive.
您已阅读13%（560字），剩余87%（3790字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。